Bluejay Therapeutics’ Founder and Chief Executive Officer Keting Chu, MD, PhD, was recently featured in the Biotech Leader Spotlight Series by Partnology. We are proud to see her remarkable accomplishments and visionary leadership in patient-focused innovation being recognized. Click through to read the interview to learn about Keting’s career journey and her current focus at Bluejay Therapeutics. #BiotechLeadership #WomenInSTEM
In this weeks Biotech Leader Spotlight Series we are recognizing Keting Chu, Founder, Chairman, and CEO of Bluejay Therapeutics! Check out her interview detailing her outstanding biotech career. Dr. Keting Chu is the Founder, CEO, and Chairman of Bluejay Therapeutics. Prior to founding Bluejay, Keting was a Venture Partner and Partner at ATP (Apple Tree Partners) and LYFE Capital briefly. Before joining Apple Tree Partners, Keting spent five years as VP, Research TAP at The Leukemia & Lymphoma Society (LLS). Prior to LLS, Keting was the CEO of Mission Therapeutics and the Co-Founder, President and CEO of DigitAB, Inc. and BioCubed Corporation. For her first startup company, Five Prime Therapeutics, Keting was Vice President of Biology and Head of R&D where she built the R&D strategy and team, established the technology platform and generated a product pipeline. Prior to Five Prime, Keting was the Head of #Immunotherapy and #Antibody Therapeutics Division at Chiron Corporation, where she engaged in #preclinical and #clinical developments of protein, #DNA-based, and small molecule therapeutics for #cancer and #inflammatory diseases. Keting received her MD in Sun Yat-Sen Medical University where she specialized in #infectious diseases in China, and PhD in Microbiology and Immunology at University of California, San Francisco. She also conducted her postdoctoral training at #Cardiovascular Research Institute at UCSF. #biotechleader #biotechexecutive #biotech #biotechnology #biopharma #womeninbio #femaleleaders #pharmaceuticals #therapeutics